Business Wire·Oct 29, 2026, 8:05 AM ET

Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians

Pennsylvania enacted House Bill 1123 to align state insurance coverage with latest American Cancer Society and National Comprehensive Cancer Center guidelines.
The law eliminates cost-sharing for approximately two million screening-eligible Pennsylvanians accessing the Guardant Health Shield blood test for colorectal cancer.
HB 1123 applies to state-regulated plans and Medicaid and becomes effective on December 21, 2026.
The Shield test is the first blood-based colorectal cancer screening option included in ACS and NCCN guidelines.
The legislation aims to address rising colorectal cancer rates among Americans under 50 by removing financial barriers to screening.
The Shield test is a non-invasive, methylation partitioning cell-free DNA blood test intended for average-risk individuals aged 45 or older.
A positive Shield result requires patients to undergo a follow-up colonoscopy for evaluation.
Bill sponsors Representative Pat Gallager and Senator Devlin Robinson emphasized that increased access to easy-to-use screening tools improves early detection rates.